Trump Administration Advances Cannabis Rescheduling After Executive Order

The Trump administration is poised to take significant action on federal cannabis policy, moving forward with the long-awaited process of marijuana rescheduling. This follows more than four months after President Trump issued an executive order instructing the Department of Justice to expedite the effort. The move marks a critical turning point in federal cannabis regulation, with broad implications for research, commerce, and criminal justice across the United States

According to Marijuana Moment, the administration's renewed push comes after repeated calls from lawmakers and advocates for federal reform. The executive order directed officials to proceed 'in the most expeditious manner,' emphasizing the urgency surrounding the issue. The rescheduling process could alter how marijuana is classified under federal law, potentially easing restrictions and opening new avenues for medical and scientific research

In Congress, momentum for cannabis research is also building. Representatives Dina Titus (D-NV) and Ilhan Omar (D-MN) have introduced a bill that would authorize $150 million to support marijuana research and permit state regulatory agencies to provide cannabis for studies. This legislative effort is designed to address longstanding barriers to scientific investigation caused by marijuana's current federal status. As Rep. Steve Cohen (D-TN) noted, there is growing consensus on "the need for federal marijuana reform."

Meanwhile, public support for legalization continues to rise. A recent poll cited by Marijuana Moment reveals that nearly 60 percent of Americans favor legalizing marijuana, with strong majorities also backing medical cannabis access. The bipartisan nature of this support underscores shifting attitudes nationwide, making federal action increasingly likely. In California, the push for innovation in cannabis retail is reflected by a bill advancing in the Assembly to permit drive-thru dispensaries, demonstrating how local and state initiatives are evolving alongside federal debates

The rescheduling process is not happening in isolation. States such as Virginia and Kentucky are advancing their own cannabis reforms, while federal lawmakers consider research funding and regulatory changes. The Drug Enforcement Administration and other agencies remain active in shaping the broader drug policy landscape, as evidenced by ongoing campaigns and guidance on related substances. Internationally, debates over drug policy and criminal prosecution continue to generate headlines, reflecting the global significance of the issue

From the OG Lab newsroom perspective, the Trump administration's decision to move forward with cannabis rescheduling could represent a seismic shift for the industry. If successful, this change may unlock new research opportunities, reduce legal risks for businesses and patients, and accelerate reforms at both state and federal levels. Industry stakeholders and policymakers will be watching closely to see how the process unfolds and what it means for the future of cannabis in the United States